STOK Stock Forecast & Price Target

Stoke Therapeutics is a promising biotechnology company with a strong pipeline and innovative TANGO platform, which has shown promising results in its first drug candidate zorevunersen. With the potential for disease modification in patients with Dravet syndrome and multiple early programs focused on haploinsufficiency diseases of the central nervous system and eye, Stoke has a broad potential market. The recent enrollment of 150 patients in its phase III EMPEROR trial and the company's strong financial position with a cash runway until 2028 are positive indications for its future success.

Stoke Therapeutics is a biotechnology company with a proprietary approach called TANGO that is focused on developing ASOs to up-regulate protein expression selectively. Its lead drug candidate, zorevunersen, targets Dravet syndrome, but has faced setbacks with an expected mid-2027 data readout. The company also has a second product, STK-002, in a phase I study for autosomal dominant optic atrophy (ADOA), but faces various risks including clinical, intellectual property, financial, stock price volatility, and commercial.